Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Analysts are intrested in these 5 stocks: ( ($MNDY) ), ( ($INCY) ), ( ($LCID) ), ( ($BE) ) and ( ($EQT) ). Here is a ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Shares of Incyte Corp. INCY slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...